Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

Exact Sciences (EXAS) PT Raised to $35 at Jefferies

April 28, 2017 10:40 AM EDT

Jefferies raised its price target on Exact Sciences (NASDAQ: EXAS) to $35.00 (from $25.00) while maintaining a Buy rating. Test volumes surged to ~100K units compared to Jefferies' ~88K expectations, reflecting a sharp acceleration from its run-rate over the past year.

EXAS raised its 2017... More

Exact Sciences (EXAS) PT Raised to $40 at Cowen; Guides Still Looks 'Very Conservative'

April 27, 2017 3:35 PM EDT

Cowen raised its price target on Exact Sciences (NASDAQ: EXAS) to $40.00 (from $30.00) while maintaining a Outperform rating following a solid start to the year.

Analyst Doug Schenkel noted revenue, new practice additions, and total orders were well ahead of expectations. In... More

Exact Sciences (EXAS) Tops Q1 EPS by 9c, Offers FY Guidance

April 27, 2017 6:23 AM EDT

Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.32), $0.09 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $48.4 million versus the consensus estimate of $37.29 million.

GUIDANCE:

Exact Sciences sees FY2017 revenue of $195-205 million, versus the consensus... More